HISUN(SH:600267) Shang Hai Zheng Quan Bao·2025-12-18 19:27Core Viewpoint - Zhejiang Hai Zheng Pharmaceutical Co., Ltd. has received a new veterinary drug registration certificate for its product, Methylprednisolone Tablets (for dogs), which is classified as a Category V new veterinary drug, indicating compliance with relevant regulations and enhancing the company's strategic positioning in the veterinary medicine sector [1][4]. Group 1: New Veterinary Drug Information - The new veterinary drug is named Methylprednisolone Tablets (for dogs) and has been approved as a Category V new veterinary drug [1]. - The registration certificate number for the new veterinary drug is (2025) New Veterinary Drug Certificate No. 129 [1]. - The drug is developed by Zhejiang Hai Zheng Animal Health Products Co., Ltd. in collaboration with seven other companies [1]. Group 2: Drug Application and Use - Methylprednisolone Tablets (for dogs) are intended for the treatment of canine inflammatory and allergic diseases, and can be part of treatment regimens for conditions such as allergic or non-specific dermatitis, musculoskeletal diseases, and inflammation of the eyes/ears [1]. - The drug is effective for various inflammatory/allergic diseases that can be treated with glucocorticoids, including immune-mediated diseases [1]. Group 3: Market Position and Future Outlook - The approval of Methylprednisolone Tablets (for dogs) is expected to enhance the company's market competitiveness in the veterinary drug sector [4]. - The product is now ready for production and market launch, pending the acquisition of the veterinary product approval number, although it is noted that it will not have a significant short-term impact on the company's performance [4].